The standard dose of a prescribed drug can cause a serious adverse response in one patient and less of a response in another. Genetic variability is directly linked to an individual's drug response. By analyzing the individual variations in the genes that produce enzymes involved in metabolizing drugs, a physician can provide a more effective treatment plan, avoiding adverse drug reaction, toxicity, or lack of drug efficacy.
Cytochrome P450 (CYP) enzymes account for 70-80% of enzymatic activity involved in drug metabolism. The genetic variations of CYP genes affect enzyme activity, which in turn affects drug metabolism. For example, CYP2D6, a member of the CYP oxidase system, was shown to be responsible for the metabolism and elimination of approximately 25% of clinically used drugs. The genetic variations (polymorphism) of the CYP2D6 genes affect its function in drug metabolisms. Thus, the identification of genetic variations of CYP and its downstream pathway components are greatly important to personalized medicine and proper treatment. Based on the ability to metabolize its substrates, an individual’s CYP2D6 function can be categorized as one of the following: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM), and ultrarapid metabolizer (UM).
Features
Assay Information
Assay method Shifted Termination Assay (STA)
Sample required 20-100 ng DNA
Assay Time 3 hours
Instrument required PCR machine and capillary sequencer ABI 3100, 3700, 3130, 3500
Order information
| Cat. No. | Product Name | Targeted SNPs | Size | Documents |
| GP03 | Warfarin genotyping kit | VKORC1 -1639G>A, CYP2C9 *2, *3 | 32 rxn | Test info |
| GP11 | CYP2D6 genotyping kit | CYP2D6 *2, *3, *4, *5, *6, *9, *10, *17, *41, 4180G>C | 32 rxn | Test info |
| GP12 | CYP2C19 genotyping kit | CYP2C19 *2, *3, *4, *5, *6, *7, *8, *17 | 32 rxn | Test info |
For research use only. Not for use in diagnostic procedures.